• 1
    Woolsley RL. Drugs that prolong the QT interval and/or induce Torsades de Pointes. Revised 11/28/2008. Accessed December 1, 2008.
  • 2
    Letsas KP, Efremidis M, Kounas SP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsades de pointes: identification of risk factors. Clin Res Cardiol. 2008.
  • 3
    Gowda RM, Khan IA, Wilbur SL, et al. Torsades de pointes: the clinical considerations. Int J Cardiol. 2004;96:16.
  • 4
    Yap YG, Cam AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:13631372.
  • 5
    Drew BJ, Califf RM, Funk M, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American heart association scientific statement from the councils on cardiovascular nursing, clinical cardiology, and cardiovascular disease in the young. Circulation. 2004;110:27212746.
  • 6
    Sommargren CE, Drew BJ. Preventing torsades de pointes by careful cardiac monitoring in hospital settings. AACN Adv Crit Care. 2007;18:285293.
  • 7
    Pickham D, Drew BJ. QT/QTc interval monitoring in the emergency department. J Emerg Med. 2008;34:428434.
  • 8
    Hutton DM. The importance of routine QT interval measurement in rhythm interpretation. Can Assoc Crit Care Nurses. 2008;19:2934.
  • 9
    Med Calc: quick, solve, diagnose. Available from: Accessed December 3, 2008.